Evotec SE

EVT

DE0005664809

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 10:05:14 06/12/2024 pm IST			5-day change	1st Jan Change
8.770 ^EUR	-1.79%		-0.68%	-58.79%

05/12	Auto1 and Evotec return to the MDax - No changes in the Dax	RE
04/12	INDEX-MONITOR: JPMorgan expects Evotec back in the MDax - Dax unchanged	DP

EVOTEC : RBC gives a Buy rating

May 22, 2024 at 09:15 pm IST

RBC analyst Charles Weston maintains his Buy rating on the stock. The target price is unchanged and still at EUR 16.

Latest news about Evotec SE

Auto1 and Evotec return to the MDax - No changes in the Dax	05/12	RE
INDEX-MONITOR: JPMorgan expects Evotec back in the MDax - Dax unchanged	04/12	DP
Sector Update: Health Care Stocks Rise in Afternoon Trading	29/11	MT
Evotec COO to Step Down by End-2024	29/11	MT
Evotec Chief Operating Officer to Step Down at End of December	29/11	MT
Evotec SE Announces Craig Johnstone to Step Down and Leave as Chief Operating Officer, Effective 31 December 2024	29/11	CI
EVOTEC : Gets a Sell rating from Deutsche Bank	25/11	ZD
Evotec Refutes Halozyme Therapeutics' Reason for Buyout Bid Withdrawal	25/11	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	23/11	MT
EVOTEC : RBC reiterates its Buy rating	22/11	ZD
Halozyme withdraws offer for pharmaceutical researcher Evotec	22/11	DP
Evotec plummets - Halozyme withdraws purchase bid	22/11	DP
Halozyme Therapeutics Withdraws Proposal to Acquire Evotec	22/11	MT
Sector Update: Health Care	22/11	MT
Halozyme Therapeutics Withdraws Proposal to Acquire Evotec	22/11	MT
Halozyme Therapeutics Withdraws Proposal to Acquire Evotec, Bloomberg Reports	22/11	MT
Halozyme withdraws $2.1 billion buyout offer for Evotec	22/11	RE
Halozyme Therapeutics, Inc. cancelled the acquisition of Evotec SE.	22/11	CI
INDEX-MONITOR/JPMorgan: Evotec likely to return to the MDax soon - Dax unchanged	21/11	DP
Recursion Pharmaceuticals, Inc. completed the acquisition of Exscientia plc.	20/11	CI
Evotec braces itself after Halozyme advances: Independence has priority	19/11	DP
Evotec weak - Possible defense battle dampens takeover fantasy	19/11	DP
EVOTEC : Deutsche Bank reiterates its Sell rating	18/11	ZD
Sector Update: Health Care Stocks Retreat Friday Afternoon	16/11	MT
Possible takeover battle boosts Evotec share price	15/11	DP

Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Employees

5,007

Sector

Biotechnology & Medical Research

Calendar

27/03/2025 - Q4 2024 Earnings Release (Projected)

More about the company